I call a truce - you are both rightThis five-dose response study will most likely test dose response both higher and lower than the single dose study – not just one (the single dose is in the middle).
Do not underestimate the results of this dose-response study.
DTP tests around 2500 compounds in vitro each year…about 50 of these compounds move on to the NCI in vivo testing program. It is THESE RESULTS we are waiting on that will determine if GAP-107B8 will be one of those 50.
Also, did everyone forget the rather unexpected results against melanoma lines?
From the single dose assay results…“Notably, 7 of 9 melanoma cell lines showed a dramatic effect, with inhibition of cell growth of 58% to 100%, with one melanoma cell line showing 100% inhibition of cell growth plus cell death in 39% of treated cells”.
Melanoma is an aggressive and difficult form of cancer to treat – survival rates are dismal and rates of melanoma are rising. Every drug company in the world would love to find a treatment option for advanced stage melanoma. Do a little reading on melanoma pharma therapy and you will see the potential here.
SP in biotech tends to fizzle around like this and then make huge leaps in the more advanced stages of development – focus on the fundamentals. GLTA